Welcome to our dedicated page for Insmed news (Ticker: INSM), a resource for investors and traders seeking the latest updates and insights on Insmed stock.
Insmed Inc (NASDAQ: INSM) is a global biopharmaceutical leader developing innovative therapies for rare pulmonary diseases and chronic inflammatory conditions. This news hub provides investors and healthcare professionals with essential updates on clinical trials, regulatory milestones, and therapeutic advancements.
Access real-time information about Insmed's FDA submissions, partnership announcements, and research breakthroughs. Our curated collection includes updates on ARIKAYCE commercialization, brensocatib clinical studies, and novel inhalation technologies like TPIP platform developments.
Key content categories include treatment approvals, scientific conference presentations, patent filings, and manufacturing expansions. All materials are sourced directly from company filings and verified industry publications to ensure accuracy.
Bookmark this page for streamlined access to Insmed's latest developments in targeted pulmonary therapy and rare disease research. Check regularly for critical updates affecting treatment accessibility and clinical progress.
Insmed (Nasdaq: INSM) reported a strong financial performance for Q4 and FY 2022, with revenues of $59.3 million and $245.4 million, respectively, reflecting a 30% annual growth, primarily driven by ARIKAYCE sales. The company completed patient screening in the Phase 3 ASPEN trial for brensocatib and expects topline results in Q2 2024. Insmed anticipates ARIKAYCE revenues to reach $285-$300 million in 2023. Despite these gains, the company reported a net loss of $160.1 million in Q4 2022. With $1.15 billion in cash reserves, Insmed is well-positioned for sustained investment in its clinical programs.
Insmed Incorporated (Nasdaq: INSM) will release its fourth quarter and full year 2022 financial results on February 23, 2023. A conference call for investors is scheduled for 8:30 a.m. ET on the same day to discuss these results and provide a business update. Interested parties can join the call by dialing (844) 200-6205 (U.S.) or (929) 526-1599 (international), or by accessing the live webcast on the company's website. A replay will be available shortly after the event until March 25, 2023. Insmed is focused on serious and rare diseases, with its first therapy already approved in the U.S., Europe, and Japan.
Insmed Incorporated (Nasdaq: INSM) announced its participation in a fireside chat at the virtual SVB Securities Global Biopharma Conference on February 14, 2023, at 12:00 p.m. ET. The event aims to highlight Insmed's commitment to transforming lives through its innovative approaches to serious and rare diseases. The chat will be accessible via the investor relations section on the company's website and will be archived for 30 days post-event. Insmed's first product treats a debilitating lung disease, with ongoing development of therapies targeting unmet medical needs.
Insmed Incorporated (Nasdaq:INSM), a biopharmaceutical company, announced on February 3, 2023, the granting of inducement awards to 18 new employees under NASDAQ Listing Rule 5635(c)(4). The awards consist of options to purchase a total of 240,010 shares at an exercise price of $21.62 per share, which reflects the closing price on the grant date. These options have a 10-year term and a four-year vesting schedule. Insmed's mission focuses on transforming the lives of patients suffering from serious and rare diseases, supported by a robust pipeline of investigational therapies.
On January 20, 2023, Insmed Incorporated (NASDAQ: INSM) announced the granting of inducement awards to 10 new employees as a material inducement for their employment. The awards, approved by the Compensation Committee, comprise options to purchase 107,580 shares at an exercise price of $19.18 per share, which aligns with the Nasdaq closing price on the grant date of January 3, 2023. The options have a 10-year term with a four-year vesting schedule, incentivizing long-term employment. Insmed focuses on therapies for serious diseases and has a pipeline targeting unmet medical needs, enhancing its market position.
Insmed Incorporated reported significant updates during the 41st Annual J.P. Morgan Healthcare Conference. The company highlighted 30% expected growth in ARIKAYCE global revenues for 2022, projecting revenues of $285 to $300 million in 2023. Phase 2 data for Brensocatib in cystic fibrosis showed a clear dose-dependent response. Additionally, a 15% treatment discontinuation rate was reported in the ARISE trial, significantly lower than prior pivotal trials. The ASPEN trial reported a blended event rate of 1.12-1.15 events per patient per year.
Insmed Incorporated (Nasdaq:INSM) will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco on January 9, 2023, at 4:30 p.m. PT (7:30 p.m. ET). The session will include a presentation and a Q&A segment, which will be streamed live via the investor relations section of Insmed's website. The webcast will remain available for 30 days post-event. Insmed focuses on transforming the lives of patients with serious and rare diseases, with its first therapy approved for a chronic lung disease and a promising pipeline for unmet medical needs.
Insmed Incorporated (Nasdaq: INSM) announced on December 6, 2022, the granting of inducement awards to 15 new employees as per NASDAQ Listing Rule 5635(c)(4). These awards, aimed at encouraging new hires, involve options to purchase a total of 89,730 shares of common stock at an exercise price of $19.12 per share. The options come with a 10-year term and a four-year vesting schedule, contingent on continued employment. Insmed focuses on therapies for serious and rare diseases, with a commitment to transforming patient lives.
Insmed Incorporated (Nasdaq: INSM), a biopharmaceutical company focused on rare diseases, will present at the Nasdaq 47th Investor Conference in London on December 7 at 8:30 a.m. EST (1:30 p.m. GMT). The presentation will be available via a live webcast on their website, with an archive lasting 30 days post-event. Insmed is dedicated to transforming patient lives through its first commercial therapy and a pipeline aimed at major unmet medical needs, particularly in pulmonary diseases.
Insmed Incorporated (Nasdaq: INSM) announced the grant of inducement awards to 18 new employees on November 4, 2022. This was in compliance with NASDAQ Listing Rule 5635(c)(4) and approved by the Compensation Committee. Each new employee received options to purchase a total of 127,060 shares of common stock at an exercise price of $17.50, the closing price on November 1, 2022. The options have a 10-year term with a four-year vesting schedule.
FAQ
What is the current stock price of Insmed (INSM)?
What is the market cap of Insmed (INSM)?
